Background {#Sec1}
==========

Ankylosing spondylitis (AS) is a chronic autoimmune disease that can result in functional and structural impairments by affecting the sacroiliac joint and the axial skeleton (Braun and Sieper [@CR5]; Danve and O\'Dell [@CR13]; Brown et al. [@CR6]). The prevalence of AS is approximately 0.24% in Europe, 0.17% in Asia, 0.32% in North America, 0.10% in Latin America, and 0.07% in Africa (Dean et al. [@CR14]). Multilevel complex interactions between genetic, epigenetic and environmental factors play important roles during AS development (Zhu et al. [@CR58]). As a chronic disease, the onset of AS is usually early and affects more men than women (Feldtkeller et al. [@CR18]). Due to the nature of AS symptoms, the lag time between symptom onset and diagnosis is 8 to 11 years. Although modern imaging techniques, anti-inflammatory agents, and physiotherapy approaches have been developed for diagnosing and treating AS, significant challenges still remain in the early diagnosis and treatment of AS (Braun and Sieper [@CR5]; Danve and O\'Dell [@CR13]).

MicroRNAs (miRNAs) are functionally important for eukaryotic cells (Bartel [@CR3]; Krol et al. [@CR32]). miRNAs typically regulate gene expression at the post-transcriptional level by dynamically interacting with different mRNAs (Zhang et al. [@CR57]; Ni and Leng [@CR43]). Since aberrant miRNA expression reflects the initiation and progression of pathological conditions, the validation of specific miRNAs as biomarkers for diseases has become a critical milestone in diagnostics (Wang et al. [@CR50]). Well-documented studies show that aberrant expression of miRNAs can contribute to the pathogenesis of AS (Lai et al. [@CR33]; Li et al. [@CR35]; Mohammadi et al. [@CR40]). Previous studies of hsa-miR-495-3p (*miR-495*) indicated its importance in cellular development and differentiation (Clark et al. [@CR12]; Li et al. [@CR34]), and it has been functionally described as a tumor suppressor in multiple tumors (Ahmadi et al. [@CR1]; Chen et al. [@CR9]; Eun et al. [@CR17]; Liu et al. [@CR36]). However, the role of *miR-495* in the pathogenesis of AS and the mechanism by which it facilitates AS pathogenesis remain elusive.

Programmed cell death 10 (*PDCD10*) protein, also known as TF-cell apoptosis-related protein 15 (*TFAR-15*), is widely expressed in different human tissues (Wang et al. [@CR51]). As the third gene locus related to cerebral cavernous malformations (CCMs), *PDCD10* is alternatively named *CCM3* (Bergametti et al. [@CR4]). Sequence conservation and binding studies suggest that *PDCD10* biases to form heterodimers with the germinal center kinase III (GCKIII) subfamily (Ceccarelli et al. [@CR8]). *PDCD10* is an essential and versatile signal transduction molecule under different physiological and pathological conditions (Huang and Zhao [@CR24]); however, its role and its relationship with *miR-495* in AS are yet to be elucidated.

In this study, the expression of *miR-495* in both AS patients and healthy controls was quantified. A high level of methylation in the promoter region of *miR-495* resulted in the lower expression of this miRNA in AS. Moreover, this miRNA can target *PDCD10* via interacting with its 3′UTR. The receiver operating characteristic (ROC) curves indicated that *miR-495*, particularly from peripheral blood mononuclear cells (PBMCs), was a highly specific and sensitive biomarker for the diagnosis of AS. Our results showed that Wnt and TGF-β signal pathways, which play essential roles in AS pathology, can be down-regulated by *miR-495*. This study suggests that *miR-495* may have application in the diagnosis and treatment of AS and provides new insight on the role of miRNAs in AS pathogenesis.

Materials and methods {#Sec2}
=====================

Study subjects {#Sec3}
--------------

This study was approved by the local institutional review board and the ethics committee of the First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan (no. 2015095).Written informed consent was obtained from all participants. Exclusion criteria included pregnancy, malignancies, other rheumatological and chronic diseases, and lack of written informed consent from the patients. This study was carried out according to the principles expressed in the Declaration of Helsinki. Patients with AS were diagnosed according to the 1984 New York Modified Criteria (van der Linden et al. [@CR49]). All subjects underwent a comprehensive physical examination, clinical chemistry analysis, and medical history before enrollment. All participant information is included in Table [1](#Tab1){ref-type="table"}. Table 1Characteristics of healthy controls (HC) and AS patientsCharacteristicsAS (*N* = 150)HC (*N* = 150)Gender (Male/Female)Male (*N* = 114)Female (*N* = 36)Male (*N* = 114)Female (*N* = 36)Age (years)M: 34.0 ± 12.5F: 32.5 ± 10.5M: 35.5 ± 10.5F: 33.5 ± 8.5Disease duration (years), mean ± SD5.5 ± 0.80HLA-B27, mean ± SD (0\~147)161.0 ± 8.5NormalESR (mm/h), mean ± SD (0\~15 for Male; 0\~20 for Female)22.5 ± 11.9NormalCRP (mg/dL), mean ± SD (1\~15)0.82 ± 0.54NormalBASDAI, mean ± SD4.43 ± 1.35NormalBASFI, mean ± SD36.8 ± 19.6NormalmSASSS13.0 ± 7.0NormalSuggestions for immunosuppressant drugs Steroids4%0 DMARDs6%0 NSAIDs100%0AS, ankylosing spondylitis; HC, healthy control; SD, Standard Deviation; HLA-B27, Human Leukocyte Antigen (HLA) B27; ESR, Erythrocyte Sedimentation Rate; CRP, C Reactive Protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity; BASFI, Bath Ankylosing Spondylitis Functionality Index; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; DMARDs, Disease-Modifying Anti-Rheumatic Drugs; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs

RNA extraction {#Sec4}
--------------

Blood samples collected from the ward were centrifuged in Ficoll solution (TBDscience, Code No: LTS1077). Then the cells were recovered from the media interface layer and washed twice with 1× phosphate buffered saline (PBS; Gibco, Code No: 20012050). Finally, cells were disrupted by RNAiso Plus (Takara, Code No: 9108) and total RNA was extracted according to the protocol. Total whole blood RNA extraction was according to the protocol (Takara, Code No: 9112). Total serum RNA was extracted according to the protocol (Qiagen, Code No: 217184), with *cel-miR-39* as a reference gene.

Quantitative real-time PCR (qPCR) {#Sec5}
---------------------------------

qPCR primers were synthesized by Shanghai Sangon Biotech. Detailed primer sequences are summarized in the Supplementary Materials (S[1](#MOESM1){ref-type="media"}). qPCR were performed according to the MIQE guidelines (Bustin et al. [@CR7]). The cDNA was synthesized with modification using PrimeScript™ RT reagent kit with gDNA eraser (Takara, Code No: RR047A) and used directly in the SYBR Green qPCR reactions (Takara, Code No: RR420A); qPCR was performed using QuantStudio™ Dx Real-Time Instrument (Applied Biosystems, Code No: 4479889).

Bisulfite-specific PCR sequencing (BSP) {#Sec6}
---------------------------------------

Bisulfite-specific PCR sequencing primers were synthesized by Shanghai Sangon Biotech. Detailed primer sequences are summarized in the Supplementary Materials (S[2](#MOESM1){ref-type="media"}). Genomic DNA was extracted according to the manufacturer's protocol (Takara, Code No: 9450). The BSP kit was obtained from TIANGEN Biotech (Code No: DP215). DNA samples with or without BSP treatments were amplified by PCR (Takara, Code No: RR02MA) and cloned into T-A plasmids (Takara, Code No: 3271) for sequencing. Four clones from each sample were sequenced.

Methylated DNA Immunoprecipitation (MeDIP) ChIP qPCR {#Sec7}
----------------------------------------------------

The Methylated DNA Immunoprecipitation (MeDIP) ChIP Kit was obtained from Abcam (Code No: ab117135). Forward and reverse primer sequences for the *miR-495*, *PDCD10*, and glyceraldehyde 3-phosphate dehydrogenase (*GADPH*) promoters are listed in the Supplementary Materials (S[3](#MOESM1){ref-type="media"}). After shearing by sonication, genomic DNA was immunoprecipitated using the Me-DIP Kit according to the manufacturer's instructions. The treated DNA was then analyzed by qPCR, as described in the previous paragraph.

Dual luciferase reporter assay {#Sec8}
------------------------------

*MiR-495* mimics and the corresponding mutants were synthesized by Genepharma (Shanghai, China). HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum and 1% streptomycin/penicillin in a humidified air atmosphere with 5% CO~2~ at 37 °C. Wild-type and mutated 3′UTRs of *PDCD10* were cloned into the psiCHECK™-2 vector (Promega, USA). All transfections were conducted with Lipo2000 (Invitrogen, USA). The dual luciferase assay kit was obtained from Beyotime Institute of Biotechnology (Jiangsu, China). The experimental procedures were according to the manufacturer's instructions. All assays were run on Glomax® (Promega, USA).

Over-expression of *miR-495* {#Sec9}
----------------------------

The adenovirus (vector: pDC316-mCMV-EGFP) carrying *miR-495* was obtained from Genechem (Shanghai, China). All the procedures were according to the manufacturer's protocol. The multiplicity of infection used was 200, and the infection time was 48 h. The infected cells were then harvested for further studies.

Primary culture of PBMCs {#Sec10}
------------------------

All the procedures followed were as per a previous report, with some modifications (Katial et al. [@CR30]). After isolation by Ficoll, PBMCs were washed and cultured in RPMI1640 containing 10% fetal bovine serum and 1% streptomycin/penicillin in a humidified air atmosphere with 5% CO~2~ at 37 °C. After 24 h, cells were infected with adenovirus, and after 48 h, washed by PBS, and collected for qPCR and western blotting.

Western blot {#Sec11}
------------

A radioimmunoassay buffer-containing cocktail was added to the collected cells. The bicinchoninic acid (BCA) assay kit (Thermo Scientific, Code No: 23225) was used to measure the concentrations of protein. After SDS-PAGE (10%), proteins were transferred to PVDF membranes (Thermo Scientific, Code No: 88518) and then incubated overnight at 4 °C in 5% nonfat milk with primary antibodies for PDCD10 (Immunoway, YN0271), β-catenin (Beyotime, AC106), TGF-β1 (Abcam, ab92486) and GADPH (Boster, M00227--5). The next day, a secondary antibody (Boster, BA1041) was used to probe the membranes. The protein bands were detected with the ECL chemiluminescence system (AmershamPharmacia Biotech, USA) and the gray values were quantified with the software Quantity One.

Bioinformatics analysis {#Sec12}
-----------------------

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed using online DAVID tools (Huang da et al. [@CR25], [@CR26]). The significant GO and signaling pathways were based on the *P* value threshold of 0.01. Predicted targets showing Pearson correlation *r* \< 0 and *P* value \< 0.05 were considered as candidates, together with targets that were experimentally validated in published reports.

Statistical analysis {#Sec13}
--------------------

Data were reported as mean [+]{.ul} SEM. Data within each cluster were analyzed with non-parametric ANOVA using Dunn's procedure. Differences between two clusters were analyzed by a nonparametric two-tailed Mann--Whitney *U*-test. The Pearson correlation coefficient was calculated to evaluate the association between *PDCD10* and *miR-495*. The ROC curves were used to evaluate the sensitivity and specificity of *miR-495*. All statistical analyses were performed using GraphPad Prism (Version 8.0, GraphPad Software, Inc). *P* values \< 0.05 were considered to indicate statistically significant differences.

Results {#Sec14}
=======

*miR-495* is down-regulated in AS {#Sec15}
---------------------------------

*miR-495* has been reported to be an anti-oncogene in multiple cancers. To evaluate *miR-495* expression, we assessed its RNA level in different biological fluids in both patients with AS and healthy controls. Previous reports show that PBMCs, whole blood, and serum can act as a source of miRNAs to study AS (Lai et al. [@CR33]; Li et al. [@CR35]; Mohammadi et al. [@CR40]). *miR-495* is significantly (*P* \< 0.01) down-regulated in PBMCs from patients with AS (Fig. [1](#Fig1){ref-type="fig"}a). The down-regulation of *miR-495* was observed in both whole blood and serum (Fig. [1](#Fig1){ref-type="fig"}b and c). Fig. 1Detection of *miR-495* expression. The expression levels were presented as the mean [+]{.ul} SD and calculated by 2^-△△ct^. **a** Expression of PBMC *miR-495*. *miR-495* expression in healthy controls and patients with AS is 1.02 [+]{.ul} 0.11 and 0.464 [+]{.ul} 0.071, respectively. **b** Expression of whole blood *miR-495*. *miR-495* expression in healthy controls and patients with AS is 0.993 [+]{.ul} 0.116 and 0.523 [+]{.ul} 0.158, respectively. **c** Expression of serum *miR-495*. *miR-495* expression in healthy controls and patients with AS is 0.813 [+]{.ul} 0.147 and 0.36 [+]{.ul} 0.162, respectively. AS: patients with ankylosing spondylitis. HC: healthy controls. *n* = 150: tested samples in each group. \*\*\*: *P* value \< 0.01

*miR-495* promoter is highly methylated {#Sec16}
---------------------------------------

To investigate the down-regulation of *miR-495* in AS, BSP was used to examine the *miR-495* promoter region. Sequences 2000 nucleotides upstream and 500 nucleotides downstream of mature *miR-495* were obtained and identified as the promoter region of *miR-495*. CpG islands of the sequences were analyzed by CpG island Searcher (<http://cpgislands.usc.edu/>) (Takai and Jones [@CR48]). In the promoter region of *miR-495*, 10 potential CpG islands were present (Fig. [2](#Fig2){ref-type="fig"}a). Following BSP, we determined that the *miR-495* promoter is highly methylated in patients with AS (Fig. [2](#Fig2){ref-type="fig"}b), with nearly 80% of the nucleotides methylated, while only about 20% were methylated in healthy controls (Fig. [2](#Fig2){ref-type="fig"}c). MeDIP ChIP qPCR also confirmed that miR-495 promoter region is highly methylated in patients with AS (Fig. [2](#Fig2){ref-type="fig"}d). Fig. 2Methylation detection of *miR-495* promoter region. All data was presented as the mean [+]{.ul} SD. **a** Sequence schema of the bisulfite-specific PCR sequenced region in the *miR-495* promoter region. Numbers (1--10) indicate potential CpG islands. **b** Methylation status of CpGs in the *miR-495* promoter region. White and black circles indicated un-methylated and methylated CpGs, respectively. AS1, AS2, AS3, AS4: different patients with AS. HC1, HC2, HC3, HC4: different healthy controls. **c** The percentage of *miR-495* promoter methylation. The percentage of *miR-495* promoter methylation in healthy controls and patients with AS was 0.79 [+]{.ul} 3.30 and 0.18 [+]{.ul} 2.63, respectively. **d** MeDIP-qPCR of *GADPH*, *miR-495*, and *PDCD10* promoters. The values of *GADPH* promoter methylation in healthy controls and patients with AS were 1.01 [+]{.ul} 0.025 and 1.10 [+]{.ul} 0.064, respectively. The values of *miR-495* promoter methylation in healthy controls and patients with AS were 0.97 [+]{.ul} 0.036 and 6.68 [+]{.ul} 0.224, respectively. The values of *PDCD10* promoter methylation in healthy controls and patients with AS were 0.93 [+]{.ul} 0.11, and 0.94 [+]{.ul} 0.028, respectively. *n* = 150 or 20: tested samples in each group. AS: patients with ankylosing spondylitis. HC: healthy controls. \*\*\*: *P* value \< 0.01

*miR-495* is negatively associated with *PDCD10* {#Sec17}
------------------------------------------------

As a potentially functional molecule in AS, it is unclear whether *miR-495* can target novel mRNAs. After a thorough analysis of StarBase, miRbase and other databases, we chose *PDCD10* for further studies (Griffiths-Jones et al. [@CR20]; Yang et al. [@CR54]). Expression of *PDCD10* is up-regulated in AS (Fig. [3](#Fig3){ref-type="fig"}a) and its mRNA level is negatively associated with *miR-495* in both patients with AS and healthy controls (Fig. [3](#Fig3){ref-type="fig"}b and c). In addition to its RNA, western blots confirmed that *PDCD10* protein levels increased in AS (Fig. [3](#Fig3){ref-type="fig"}d). These results indicated that *PDCD10* is up-regulated in AS, acting as a potential target of *miR-495*. Fig. 3Expression of *PDCD10*. **a** qPCR of *PDCD10*. The expression levels were presented as the mean [+]{.ul} SD and calculated by 2^-△△ct^. *PDCD10* expression in healthy controls and patients with AS was 1.01 [+]{.ul} 0.116 and 1.68 [+]{.ul} 0.241, respectively. **b** Correlation analysis between *PDCD10* and *miR-495* expression in patients with AS. **c** Correlation analysis between *PDCD10* and *miR-495* expression in healthy controls. **d** Western blot of *PDCD10*. HC-1, HC-2, HC-3: different healthy controls. AS-1, AS-2, AS-3: different patients with AS. *GADPH* used as internal reference. The *PDCD10* protein levels were also showed as the histogram. *n* = 150 or 6: tested samples in each group. PBMCs: peripheral blood mononuclear cells. AS: patients with ankylosing spondylitis. HC: healthy controls. \*\*\*: *P* value \< 0.01

miR-495 can target PDCD10 {#Sec18}
-------------------------

In order to confirm whether *miR-495* can target *PDCD10*, in vitro tests were employed. Dual luciferase reporter assays were used to validate the target sites of *miR-495* using *miR-495* mimics, mutated *miR-495*, *PDCD10* 3'UTR, and the corresponding 3'UTR mutation (Fig. [4](#Fig4){ref-type="fig"}a); our results showed that *miR-495* mimics can strongly inhibit the *PDCD10* 3'UTR in comparison to other groups (Fig. [4](#Fig4){ref-type="fig"}b). The dual luciferase assays performed in Jurkat cells were consistent with this result (Supplementary Materials Fig. [1](#MOESM1){ref-type="media"}). Thus, the results of the dual luciferase reporter assays suggested that *miR-495* can efficiently inhibit luciferase by interacting with *PDCD10* 3'UTR. Fig. 4Validation the interaction between *PDCD10* and *miR-495*. **a** Schema of the interaction between *miR-495* and *PDCD10* 3′UTR. Black vertical lines and red bases indicate the interacting regions. Mutated bases are marked with green letters. **b** Dual luciferase report assay results. Vector PDCD10 and VectorMut-PDCD10 indicate plasmid with wild-type and mutated *PDCD10* 3′UTR, respectively. MiR-495 PDCD10 indicates the interaction between wild-type *miR-495* and wild-type *PDCD10* 3′UTR. MiR-495 Mut-PDCD10 indicates the interaction between wide type *miR-495* and mutated *PDCD10* 3′UTR. Mut-miR-495 PDCD10 indicates the interaction between mutated *miR-495* and wild-type *PDCD10* 3′UTR. Mut-miR-495 Mut-PDCD10 indicates the interaction between mutated *miR-495* and mutated *PDCD10* 3′UTR. **c** Transfection of primary PBMCs from AS. Top picture: bright field image of transfected PBMCs. Bottom picture: fluorescence image of transfected PBMCs. **d** Detection of *miR-495* in transfected primary PBMCs from AS. Mock: untreated group. Vector: blank vector group. Control: mutated *miR-495* over-expression group. MiR-495: *miR-495* over-expression group. **e** RNA detection of *PDCD10* in transfected primary PBMCs from AS. Mock: untreated group. Vector: blank vector group. Control: mutated *miR-495* over-expression group. MiR-495: *miR-495* over-expression group. **f** Western blot of *PDCD10* in transfected primary PBMCs from AS. Mock: untreated group. Vector: blank vector group. Control: mutated *miR-495*over-expression group. MiR-495: *miR-495* over-expression group. *n* = 6: repeated times. \*\*\*: *P* value \< 0.01

Another in vitro experiment tested the over-expression of *miR-495* from adenovirus in primary cultures of PBMCs from patients with AS. The transfection efficiency was evaluated by the detection of *miR-495* expression and the green fluorescent protein (*GFP*) reporter gene. *GFP* and qPCR of *miR-495* showed that the transfection efficiency of the adenovirus was very high (Fig. [4](#Fig4){ref-type="fig"}c and d). The mRNA and protein expression of *PDCD10* was assessed. qPCR suggested that there was a minor effect on the *PDCD10* mRNA level (Fig. [4](#Fig4){ref-type="fig"}e), while the *PDCD10* protein expression is significantly repressed (*P* \< 0.01) (Fig. [4](#Fig4){ref-type="fig"}f). *miR-495* seems to significantly inhibit the translation of *PDCD10*, while having little effect on its mRNA level.

ROC curves of *miR-495* {#Sec19}
-----------------------

In order to evaluate the specificity and sensitivity of *miR-495* in AS diagnosis, different ROC curves of *miR-495* were plotted. The area under the ROC curve (AUC) for *miR-495* of PMBCs was 0.7849 (95% CI: from 0.7315 to 0.8384, *P* value \< 0.0001) (Fig. [5](#Fig5){ref-type="fig"}a). The AUC of whole blood *miR-495* was found to be 0.6576 (95% CI: from 0.5894 to 0.7258, *P* value \< 0.0001) (Fig. [5](#Fig5){ref-type="fig"}b). The AUC of serum *miR-495* was 0.6052 (95% CI: from 0.5350 to 0.6755, *P* value = 0.0028) (Fig. [5](#Fig5){ref-type="fig"}c). Fig. 5ROC curves of *miR-495*. **a** ROC curve of PBMC *miR-495*. **b** ROC curve of whole blood *miR-495*. **c** ROC curve of serum *miR-495*. **d** Summary of miR-495 specificity and sensitivity. Youden index was used to evaluate the tested methods. And the Jordan index = sensitivity [+]{.ul} specificity-1. When the maximum value of the Jordan index was determined, the corresponding specificity and sensitivity rates of ROC curve were also achieved. PBMCs: peripheral blood mononuclear cells; ROC: receiver operating characteristic. Area, Std. Error, 95% confidence interval, *P* value, Jordan index, specificity, and sensitivity were indicated as shown

The AUC values show that PBMC *miR-495* is more specific and sensitive than whole blood or serum *miR-495* for AS diagnosis. Then, the specificity and sensitivity of *miR-495* were calculated. The specificity and sensitivity of *miR-495* in the different blood components were 0.61 and 0.96, respectively, in PBMCs; 0.53 and 0.98, respectively, in whole blood; and 0.49 and 0.85, respectively, in serum (Fig. [5](#Fig5){ref-type="fig"}d). In most AS studies, miRNAs are sourced from PBMCs (Li et al. [@CR35]; Mohammadi et al. [@CR40]). The concentration of miRNAs in serum RNAs may be too low for efficient isolation and amplification. While a higher target concentration would be present in whole blood, this would be limited by the high level of RNA in whole blood, which may account for limited use of whole blood in AS diagnosis.

*miR-495* can down-regulate β-catenin and TGF-β1 {#Sec20}
------------------------------------------------

In order to explore the potential role of *miR-495* in AS, we used all confirmed and predicted targets of *miR-495* based on KEGG and GO analysis. Signaling pathway analysis determined that *miR-495* participates in multiple pathways (Fig. [6](#Fig6){ref-type="fig"}a, b and c). Biological processes analysis suggested that *miR-495* is versatile in gene expression regulation (Fig. [6](#Fig6){ref-type="fig"}d). Fig. 6Exploring the potential role of *miR-495***. a** Classical signaling pathway analysis. **b** Signaling pathways related to disease analysis. **c** Other signaling pathway analysis. Signaling pathways were analyzed by KEGG with a *P* value threshold of 0.01. **d** GO categories of *miR-495*. The -log *P* value came from enrichment analysis. The 39 GO categories (biological processes) were all with a *P* value threshold of 0.01. **e** Western blot of β-catenin and TGF-β1. AS1, AS2, and AS3: different patients with AS. Healthy controls were indicated as HC1, HC2, and HC3. *n* = 3: repeated samples in each group. *P* values were indicated as shown. **F** Western blot of β-catenin in transfected primary PBMCs. Mock: untreated group. Vector: blank vector group. Control: mutated *miR-495* over-expression group. MiR-495: *miR-495* over-expression group. **g** Western blot of TGF-β1 in transfected primary PBMCs. Mock: untreated group. Vector: blank vector group. Control: mutated *miR-495* over-expression group. MiR-495: *miR-495* over-expression group

Following these analyses, the Wnt and TGF-β signal pathways were chosen for further studies. Firstly, β-catenin and TGF-β1 were detected in both AS and healthy controls, suggesting that both the related signal pathways are activated in AS (Fig. [6](#Fig6){ref-type="fig"}e). Then, the influence of *miR-495* on these same signal pathways was examined. The adenovirus containing over-expressed *miR-495* was used to infect the primary PBMCs from patients with AS. The results indicate that over-expressed *miR-495* can strongly inhibit the expression of β-catenin and TGF-β1 (Fig. [6](#Fig6){ref-type="fig"}f and g). Considering the heterogeneity of PBMCs, flow cytometry was used to assess the cell population. Our results showed that the number of lymphocytes varies between healthy controls and patients with AS (Supplementary Materials Fig. [2](#MOESM1){ref-type="media"}). Thus, we speculated that lymphocytes are more relevant for *miR-495* function in AS pathogenesis.

Discussion {#Sec21}
==========

Abnormal expression of miRNAs has been deemed to be important in the pathogenesis of AS, though their exact roles are still not fully understood. Studies from Xu et al. ([@CR52]) and Qian et al. ([@CR45]) indicated that there was a strong association between AS and *miR-146a/rs2910164*, while the results from Niu et al. ([@CR44]) did not support this conclusion (Niu et al. [@CR44]; Xu et al. [@CR52]; Qian et al. [@CR45]). The levels of *miR-29a* have been shown to be elevated in PBMCs (Huang et al. [@CR28]), whereas in other studies they have been reported to be significantly lower (Lv et al. [@CR37]). However, recent studies on AS supported an increased expression of *miR-29a* in PBMCs (Huang et al. [@CR27], Yang et al. [@CR55]). Ma et al. ([@CR38]) found that *miR-132* is down-regulated in plasma; nevertheless, Guo et al. ([@CR21]) showed that *miR-132* is up-regulated in PBMCs (Ma et al. [@CR38]; Guo et al. [@CR21]). These divergent results may depend on the stages of AS, methods used, samples type (serum, plasma, PBMC, and whole blood) or the specific expression of miRNAs. In this study, our results suggested that *miR-495* is down-regulated in different biological fluids in patients with AS and the expression of *miR-495* in PBMCs is likely to be more stable than that in other blood components. These studies also suggested that miRNAs involved in AS have a more complex role than anticipated.

Previous studies on *miR-495* and its targeted mRNAs indicated it is versatile under diverse physiological and pathological conditions: its up-regulation was detected in diverse cardiomyopathies and its inhibitor (antimiR) can attenuate pathological hypertrophy (Clark et al. [@CR12]). Up-regulated *miR-495* can induce senescence of mesenchymal stem cells derived from patients with pre-eclampsia by targeting *Bmi-1* mRNA (Li et al. [@CR34]). In breast cancer, up-regulated *miR-495* can inhibit cell proliferation and promote apoptosis by targeting *STAT-3* (Chen et al. [@CR9]). In osteoarthritis, up-regulated *miR-495* can promote chondrocyte apoptosis through inhibition of the NF-*k*B signaling pathway by targeting *CCL4* (Yang et al. [@CR53]). In this study, over-expressed *miR-495* decreased β-catenin and TGF-β1 levels, although the detailed mechanism is still unclear. Among the potential mechanisms, an alteration of the Wnt and TGF-β signal pathways seemed the most feasible, since these pathways had well-documented and essential roles in AS (Howe et al. [@CR23]; Shehata et al. [@CR46]; Diarra et al. [@CR16]; Maripat.Corr [@CR39]). Functional studies of *miR-495* could highlight its potential clinical application as a biomarker or therapeutic target in AS. We would thus like to explore all these potential interactions by high-throughput sequencing of RNAs isolated by cross-linking immunoprecipitation (HITS-CLIP), a method for decoding all microRNA-mRNA interaction maps (Chi et al. [@CR10]; Moore et al. [@CR42]).

Programmed cell death 10 protein is an important and versatile signal transduction regulating molecule (Huang and Zhao [@CR24]). Under oxidative stress, *PDCD10* can affect the cellular levels of mammalian STE20-like protein kinase 4 (*MST4*) and protect cells from reactive oxygen species (Fidalgo et al. [@CR19]). Conversely, *PDCD10* has been implicated in accelerating apoptosis via interacting with serine/threonine protein kinase 25 (*STK25*) under oxidative stress (Zhang et al. [@CR56]). Based on previous functional studies of *miR-495*, it is reasonable to infer that *PDCD10* might promote cell growth in AS. Understanding the involvement of *PDCD10* in AS and its interactions with miRNAs is a potential avenue for further studies.

Nationwide population-based cohort studies show that patients with AS have a higher risk of developing cancer, acute coronary syndrome, Asthma, atrial fibrillation, and venous thromboembolism (Chou et al. [@CR11], Shen et al. [@CR47], Avina-Zubieta et al. [@CR2], Huang et al. [@CR29], Moon et al. [@CR41]). A systematic review and meta-analysis also confirms that patients with AS are at highest risk for malignancy overall (Deng et al. [@CR15]). *miR-495* is down-regulated in multiple diseases in the experimentally supported human microRNA disease database (Huang et al. [@CR29]). As a potential biomarker in AS, *miR-495* showed high sensitivity but low specificity in all kinds of tissue detected. A well-studied biomarker, C-reactive protein (CRP), is a sensitive and valuable nonspecific indicator of most forms of tissue damage, inflammation, and infection, reflecting a broad range of diverse pathologic processes (Koenig and Pepys [@CR31]). Thus, it may be desirable to favor sensitivity over specificity for the early, less expensive, noninvasive tests (Hartwell et al. [@CR22]).

Conclusions {#Sec22}
===========

In conclusion, our study confirmed that *miR-495* down-regulation could be used as a potential molecular biomarker in AS diagnosis and treatment. This study provided insights into the role of *miR-495* in AS as well as its interaction with PDCD10, but the precise mechanism of action of miR-495 and clinical applications require further experimental investigation.

Supplementary information
=========================

 {#Sec23}

**Additional file 1: Figure S1.** Dual luciferase assays in Jurkat cells. Mock: untreated group. MiR-495 PDCD10 indicated wild-type miR-495 and PDCD10 3'UTR. MiR-495 Mut-PDCD10 indicated wide type miR-495 and mutated PDCD10 3'UTR. Mut-miR-495 PDCD10 indicated mutated miR-495 and wild type PDCD10 3'UTR. Mut-miR-495 Mut-PDCD10 indicated mutated miR-495 and mutated PDCD10 3'UTR. The test was repeated six times independently (n=6). \*\*\*: *P* value \< 0.01. **Figure S2.** Flow cytometry analysis of PBMCs. Fluorescent labeled anti CD3 monoclonal antibody (BD Biosciences) was combined with PBMCs to detect the expression of CD3 antigen on the lymphocytes cell surface by flow cytometer (BD Biosciences). The number of AS lymphocytes was more than the healthy controls. **Table S1.** Primers used in this study. The table was separated by 3 columns: Gene name, RT primer (From 5' to 3'), Forward primer (From 5' to 3'). **Table S2.** Primers used in Bisulfite-specific PCR sequencing (BSP). The table was separated by 3 columns: Gene name, Forward primer (From 5' to 3'). **Table S3.** Primers used in Methylated DNA Immunoprecipitation (MeDIP) ChIP qPCR. The table was separated by 3 columns: Gene name, Forward primer (From 5' to 3').
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:   Hsa-miR-495-3p

qPCR

:   Quantitative real-time PCR

PBMCs

:   Peripheral Blood Mononuclear Cells

BSP

:   Bisulfite-specific PCR sequencing

MeDIP

:   methylated DNA immunoprecipitation

ROC

:   Receiver Operating Characteristic

PDCD10

:   Programmed Cell Death

GO

:   Gene Ontology

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

CCMs
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